Sustained activation of the reverse transsulfuration pathway has been implicated in the resistance of ovarian cancer cells to erastin-induced ferroptosis.226 CH004, a pharmacological inhibitor of CBS, has been identified as a novel stimulator of ferroptosis in liver cancer both in vitro and in vivo,227 providing experimental evidence to support the therapeutic potential of targeting the transsulfuration pathway in liver cancer. The gene discussed is CBS; the disease is liver cancer.